Acinetobacter Pneumonia

Introduction
Acinetobacter species, particularly Acinetobacter baumannii, are opportunistic pathogens commonly associated with hospital-acquired and ventilator-associated pneumonia. They are highly resistant to multiple drug classes, making treatment challenging. Management requires rapid identification, appropriate empiric coverage in high-risk settings, and targeted therapy based on culture and susceptibility results. Supportive measures and infection-control precautions are equally important to improve outcomes and prevent spread.

1. Empiric Antimicrobial Therapy

• Initiated in critically ill patients at high risk for multidrug-resistant (MDR) infection, especially in intensive care units.

• Carbapenems (imipenem, meropenem): Historically first-line, though resistance is increasingly common.

• Ampicillin–sulbactam: May retain activity in some MDR isolates and used as a preferred option when susceptible.

• Extended-spectrum cephalosporins (e.g., cefepime, ceftazidime): Considered if susceptibility is confirmed.

2. Directed Therapy for MDR/XDR Strains

• Polymyxins (colistin, polymyxin B): Often reserved for extensively resistant isolates. Administered IV; inhaled colistin may be added for ventilator-associated pneumonia.

• Tigecycline: Active against some MDR strains, though limited by suboptimal serum concentrations; higher-dose regimens may be used in severe pneumonia.

• Minocycline: An alternative tetracycline derivative with reported efficacy against MDR A. baumannii.

• Cefiderocol: A siderophore cephalosporin effective against carbapenem-resistant Acinetobacter; used in severe or resistant cases.

• Combination therapy: Sometimes employed (e.g., colistin + carbapenem, or sulbactam + tigecycline) to enhance activity and reduce resistance risk, though evidence is mixed.

3. Adjunctive and Supportive Measures

• Ventilatory support: For patients with respiratory failure or ventilator-associated pneumonia.

• Fluid management: To maintain hemodynamic stability.

• Oxygen therapy: As indicated to maintain adequate oxygenation.

• Nutritional and metabolic support: Critical in prolonged ICU admissions.

4. Infection Control and Prevention

• Strict adherence to hand hygiene and contact precautions in healthcare facilities.

• Environmental decontamination, as Acinetobacter can survive for long periods on surfaces.

• Antimicrobial stewardship to prevent the development and spread of resistant strains.

• Surveillance cultures in high-risk ICU settings to guide empiric therapy.

5. Multidisciplinary Care

• Infectious disease specialists for guidance on antibiotic selection and duration.

• Critical care physicians for ventilatory and hemodynamic management.

• Clinical pharmacists for dose optimization, especially with colistin and combination regimens.